Glenmark Pharma

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE935A01035
  • NSEID: GLENMARK
  • BSEID: 532296
INR
1,965.75
-8.4 (-0.43%)
BSENSE

Dec 05

BSE+NSE Vol: 4.41 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationHalf Yearly Results
Results Snapshot
Figures in Cr
Consolidate Half Yearly Results
Sep'25
Sep'24
Sep'23
Sep'22
Sep'21
Sep'20
Sep'19
Net Sales
9,311.31
6,677.98
6,243.45
5,482.54
6,112.34
5,297.27
5,137.92
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
9,311.31
6,677.98
6,243.45
5,482.54
6,112.34
5,297.27
5,137.92
Raw Material Cost
1,454.97
1,460.13
1,746.01
1,612.90
1,768.62
1,569.03
1,255.26
Purchase of Finished goods
1,201.79
803.11
827.26
609.57
604.86
319.46
537.51
(Increase) / Decrease In Stocks
-376.67
-83.08
-187.69
-187.01
-90.96
-39.41
3.48
Employee Cost
1,849.01
1,497.01
1,414.15
1,279.56
1,283.75
1,209.86
1,173.29
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
-0.01
0.00
0.00
-0.01
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Expenses
2,242.15
1,810.68
1,544.08
1,404.47
1,382.33
1,207.44
1,376.06
Total Expenditure (Excl Depreciation)
6,371.24
5,487.85
5,343.81
4,719.48
4,948.60
4,266.38
4,345.60
Operating Profit (PBDIT) excl Other Income
2,940.07
1,190.13
899.64
763.06
1,163.74
1,030.89
792.32
Other Income
227.07
70.91
21.42
260.77
45.58
26.63
82.49
Operating Profit (PBDIT)
3,167.14
1,261.04
921.06
1,023.83
1,209.32
1,057.52
874.81
Interest
124.69
88.06
233.07
142.79
144.55
174.37
182.79
Exceptional Items
-1,708.35
0.00
-377.45
0.00
0.00
31.13
0.00
Gross Profit (PBDT)
1,334.10
1,172.98
310.54
881.04
1,064.77
914.28
692.02
Depreciation
271.13
238.07
283.49
282.65
236.26
217.29
184.89
Profit Before Tax
1,062.98
934.91
27.05
598.39
828.51
696.99
507.14
Tax
405.57
240.18
-84.52
108.61
247.18
208.95
142.31
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
657.41
694.72
111.57
489.78
581.33
488.04
364.82
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
657.41
694.72
111.57
489.78
581.33
488.04
364.82
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
-0.18
-0.24
-43.58
-36.81
-17.11
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
657.22
694.48
67.99
452.97
564.22
488.04
364.82
Equity Capital
28.22
28.22
28.22
28.22
28.22
28.22
28.22
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Earnings per share (EPS)
23.29
24.61
2.41
16.05
19.99
17.29
12.93
Diluted Earnings per share
23.28
24.61
-6.6
16.05
20.0
17.3
12.93
Operating Profit Margin (Excl OI)
32.44%
17.97%
14.61%
14.1%
19.17%
19.76%
15.7%
Gross Profit Margin
14.72%
17.71%
5.04%
16.28%
17.54%
17.52%
13.71%
PAT Margin
7.25%
10.49%
1.81%
9.05%
9.57%
9.35%
7.23%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Half Yearly Analysis Highlights
stock-summary

Net Sales

Growth in half year ended Sep 2025 is 39.43% vs 6.96% in Sep 2024

stock-summary

Consolidate Net Profit

Growth in half year ended Sep 2025 is -5.37% vs 921.44% in Sep 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

Growth in half year ended Sep 2025 is 147.04% vs 32.29% in Sep 2024

stock-summary

Interest

Growth in half year ended Sep 2025 is 41.60% vs -62.22% in Sep 2024

stock-summary

Operating Profit Margin (Excl OI)

Growth in half year ended Sep 2025 has improved from Sep 2024

Compare Half Yearly Results Of Glenmark Pharma With
Markets Mojo
Figures in Cr
Consolidate Half Yearly Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Net Sales
9,311.31
0
9,311.31
Other Operating Income
0.00
0.00
0.00
Total Operating income
9,311.31
0
9,311.31
Raw Material Cost
1,454.97
0
1,454.97
Purchase of Finished goods
1,201.79
0
1,201.79
(Increase) / Decrease In Stocks
-376.67
0
-376.67
Employee Cost
1,849.01
0
1,849.01
Power Cost
0.00
0
0.00
Manufacturing Expenses
-0.01
0
-0.01
Selling and Distribution Expenses
0.00
0
0.00
Other Expenses
2,242.15
0.00
2,242.15
Total Expenditure (Excl Depreciation)
6,371.24
0
6,371.24
Operating Profit (PBDIT) excl Other Income
2,940.07
0.00
2,940.07
Other Income
227.07
0
227.07
Operating Profit (PBDIT)
3,167.14
0
3,167.14
Interest
124.69
0
124.69
Exceptional Items
-1,708.35
0
-1,708.35
Gross Profit (PBDT)
1,334.10
0
1,334.10
Depreciation
271.13
0
271.13
Profit Before Tax
1,062.98
0
1,062.98
Tax
405.57
0
405.57
Provisions and contingencies
0.00
0
0.00
Profit After Tax
657.41
0
657.41
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0.00
0
0.00
Other Adjustments
0.00
0
0.00
Net Profit
657.41
0
657.41
Share in Profit of Associates
0.00
0
0.00
Minority Interest
-0.18
0
-0.18
Other related items
0.00
0.00
0.00
Consolidated Net Profit
657.22
0
657.22
Equity Capital
28.22
0
28.22
Face Value
1.00
0
0.00
Reserves
0.00
0
0.00
Earnings per share (EPS)
23.29
0
23.29
Diluted Earnings per share
23.28
0
23.28
Operating Profit Margin (Excl OI)
32.44%
0%
0.00
32.44%
Gross Profit Margin
14.72%
0%
0.00
14.72%
PAT Margin
7.25%
0%
0.00
7.25%
Public Share Holdings (%)
0.00%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0%
0.00
0.00%
Half Yearly - Net Sales
Net Sales 9,311.31 Cr
in Sep 2025

Figures in Cr
stock-summary

Growth in half year ended Sep 2025 is 39.43% vs 6.96% in Sep 2024

Half Yearly - Consolidate Net Profit
Consolidate Net Profit 657.22 Cr
in Sep 2025

Figures in Cr
stock-summary

Growth in half year ended Sep 2025 is -5.37% vs 921.44% in Sep 2024

Half Yearly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 2,940.07 Cr
in Sep 2025

Figures in Cr
stock-summary

Growth in half year ended Sep 2025 is 147.04% vs 32.29% in Sep 2024

Half Yearly - Interest
Interest 124.69 Cr
in Sep 2025

Figures in Cr
stock-summary

Growth in half year ended Sep 2025 is 41.60% vs -62.22% in Sep 2024

Half Yearly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 32.44%
in Sep 2025

Figures in %
stock-summary

Growth in half year ended Sep 2025 has improved from Sep 2024